Psychopharmacotherapy of panic disorder: 8-week randomized trial with clonazepam and paroxetine
Open accessThe DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
The objective of the present randomized, open-label, naturalistic 8-week study was to compare the efficacy and safety of treatment with clonazepam (N = 63) and paroxetine (N = 57) in patients with panic disorder with or without agoraphobia. Efficacy assessment included number of panic attacks and clinician ratings of the global severity of panic disorders with the clinical global impression (CGI) improvement (CGI-I) and CGI severity (CGI-S) scales. Most patients were females (69.8 and 68.4% in the clonazepam and paroxetine groups, respectively) and age (mean ± SD) was 35.9 ± 9.6 years for the clonazepam group and 33.7 ± 8.8 years for the paroxetine group. Treatment with clonazepam versus paroxetine resulted in fewer weekly panic attacks at week 4 (0.1 vs 0.5, respectively; P < 0.01), and greater clinical improvements at week 8 (CGI-I: 1.6 vs 2.9; P = 0.04). Anxiety severity was significantly reduced with clonazepam versus paroxetine at weeks 1 and 2, with no difference in panic disorder severity. Patients treated with clonazepam had fewer adverse events than patients treated with paroxetine (73 vs 95%; P = 0.001). The most common adverse events were drowsiness/fatigue (57%), memory/concentration difficulties (24%), and sexual dysfunction (11%) in the clonazepam group and drowsiness/fatigue (81%), sexual dysfunction (70%), and nausea/vomiting (61%) in the paroxetine group. This naturalistic study confirms the efficacy and tolerability of clonazepam and paroxetine in the acute treatment of patients with panic disorder.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Quality of Life in Individuals With Anxiety Disorders
Mendlowicz, M. V., & Stein, M. B. (2000) · American Journal of Psychiatry · doi:10.1176/appi.ajp.157.5.669 · Cited by 955 · cited 3×
“Excessive sweating 2 (3) 0 0 18 (32) 17 1 **”
BackgroundRemission Rates in Patients With Anxiety Disorders Treated With Paroxetine
Ballenger, J. C. (2004) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v65n1216 · Cited by 82
Treatment-Resistant Panic Disorder
Bandelow, B., & Rüther, E. (2004) · CNS Spectrums · doi:10.1017/s1092852900022379 · Cited by 57 · cited 1×
“br Braz J Med Biol Res 44(4) 2011 remain symptomatic and this proportion may be higher in the naturalistic setting (9).”
BackgroundThe Role of High-Potency Benzodiazepines in the Treatment of Panic Disorder
Susman, J., & Klee, B. (2005) · The Primary Care Companion For CNS Disorders · doi:10.4088/pcc.v07n0101 · Cited by 39 · cited 7×
“Previous reports indicate a high level of relapse following discontinuation of panic disorder pharmacotherapy (6,13,14).”
BackgroundResultInfluential
Cited by
Katzman, M. A., Bleau, P., Blier, P., Chokka, P., Kjernisted, K., Van Ameringen, M., & the Canadian Anxiety Guidelines Initiative Group on behalf of the Anxiety Disorders Association of Canada/Association Canadienne des troubles anxieux and McGill University (2014) · BMC Psychiatry · doi:10.1186/1471-244x-14-s1-s1 · Cited by 1,090
Offidani, E., Guidi, J., Tomba, E., & Fava, G. A. (2013) · Psychotherapy and Psychosomatics · doi:10.1159/000353198 · Cited by 166
Bandelow, B., Allgulander, C., Baldwin, D. S., Costa, D. L. D. C., Denys, D., Dilbaz, N., Domschke, K., Eriksson, E., Fineberg, N. A., Hättenschwiler, J., et al. (2023) · The World Journal of Biological Psychiatry · doi:10.1080/15622975.2022.2086295 · Cited by 158
Self-citationThe reappraisal of benzodiazepines in the treatment of anxiety and related disorders
Starcevic, V. (2014) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.2014.963057 · Cited by 90
“In doing so, they seem to ignore evidence that BDZs are often better tolerated than SSRIs and SNRIs [21,25,28–31,54], further overestimating the problems arising in the course of treatment with BDZs and underestimating the problems occurring during the treatment with SSRIs and SNRIs.”
BackgroundRisks and benefits of medications for panic disorder: A comparison of SSRIs and benzodiazepines
Quagliato, L. A., Freire, R. C., & Nardi, A. E. (2018) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2018.1429403 · Cited by 62
“The most common side effects reported in the clonazepam group were difficulties in memory and concentration [55,56].”
Background
Metadata
- Authors
- Nardi, A. E., Valença, A. M., Freire, R. C., Mochcovitch, M. D., Amrein, R., Sardinha, A., Levitan, M. N., Nascimento, I., de-Melo-Neto, V. L., King, A. L., de O. e Silva, A. C., Veras, A. B., Dias, G. P., Soares-Filho, G. L., da Costa, R. T., Mezzasalma, M. A., de Carvalho, M. R., de Cerqueira, A. C., Hallak, J. E., Crippa, J. A., & Versiani, M.
- Venue
- Brazilian Journal of Medical and Biological Research
- Publisher
- FapUNIFESP (SciELO)
- Published
- 2011-04
- Volume
- 44
- Issue
- 4
- Pages
- 366-373
- ISSN
- 0100-879X (ISSN-L)
- 1414-431X
- OpenAlex
- W4247026698
- Cited by
- 39
- References
- 4
- FWCI
- 3.95
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Psychopharmacotherapy of panic disorder: 8-week randomized trial with clonazepam and paroxetine. https://app.cochat.ai/papers/10.1590/s0100-879x2011000400015
- The paper
- Nardi, A. E., Valença, A. M., Freire, R. C., Mochcovitch, M. D., Amrein, R., Sardinha, A., Levitan, M. N., Nascimento, I., de-Melo-Neto, V. L., King, A. L., de O. e Silva, A. C., Veras, A. B., Dias, G. P., Soares-Filho, G. L., da Costa, R. T., Mezzasalma, M. A., de Carvalho, M. R., de Cerqueira, A. C., Hallak, J. E., . . . Versiani, M. (2011). Psychopharmacotherapy of panic disorder: 8-week randomized trial with clonazepam and paroxetine. Brazilian Journal of Medical and Biological Research. https://doi.org/10.1590/s0100-879x2011000400015
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.